Sergio Duron is a Managing Partner with Avalon BioVentures (ABV) and has over 20 years of drug discovery experience. He joined various Avalon portfolio companies in 2008, where he had operational roles across multiple funds and became a partner at ABV in 2022. In addition to his role at ABV, he also serves as CEO for Enlaza Therapeutics. Previously, he was CSO and cofounder at Nerio (acquired by Boehringer Ingelheim), Calporta (acquired by Merck), and Anexigen. He was also Senior Vice President at Sitari (acquired by GSK) and at Sova, Vice President at Afraxis (acquired by Genentech), and Director of Chemistry at Zacharon (acquired by BioMarin). Prior to joining ABV, Dr. Duron was a scientist at Kalypsys, where he worked on multiple drug discovery projects spanning CNS diseases, pain and inflammation, metabolic diseases, and oncology.

Dr. Duron conducted postdoctoral research at The Scripps Research Institute after receiving his Ph.D. in organic chemistry from the University of Illinois at Urbana-Champaign and his B.S. in chemistry from the University of Texas at Austin.